CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.229
-0.001 (-0.43%)
Mar 9, 2026, 1:22 PM EST
CytoDyn Employees
CytoDyn had 13 employees as of May 31, 2025. The number of employees increased by 4 or 44.44% compared to the previous year.
Employees
13
Change (1Y)
4
Growth (1Y)
44.44%
Revenue / Employee
n/a
Profits / Employee
-$3,103,462
Market Cap
296.04M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Northwest Biotherapeutics | 25 |
| Vaxart | 105 |
| Nuo Therapeutics | 9 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
| ZIVO Bioscience | 7 |
| Harvard Apparatus Regenerative Technology | 8 |
CytoDyn News
- 4 days ago - CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab - GlobeNewsWire
- 17 days ago - CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference - GlobeNewsWire
- 5 weeks ago - CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer - GlobeNewsWire
- 2 months ago - December 2025 Letter to Shareholders - GlobeNewsWire
- 3 months ago - CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 3 months ago - CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 4 months ago - CytoDyn Secures $30 Million Commitment from Yorkville Advisors - GlobeNewsWire
- 4 months ago - Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire